Actively Recruiting
Single Dose Escalation Study of CM383 in Healthy Volunteers
Led by Keymed Biosciences Co.Ltd · Updated on 2024-11-08
56
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single center, randomized, double-blind, placebo-controlled Phase I clinical study in a single dose escalation to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in male healthy subjects.
CONDITIONS
Official Title
Single Dose Escalation Study of CM383 in Healthy Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy males who voluntarily agree to participate
- Between 18 and 80 years old (inclusive)
- Able to communicate well with researchers and follow study requirements
You will not qualify if you...
- Smoking more than 5 cigarettes daily on average within 3 months before screening
- Excessive alcohol use within 3 months before screening or positive alcohol breath test
- Positive urine drug abuse screening
- Planning family or sperm donation or unwilling to use effective contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jinan Central Hospital
Jinan, Shandong, China
Actively Recruiting
Research Team
Q
Qian Jia
CONTACT
Q
Qing Wen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here